

Simplification to Atazanavir + Ritonavir + Lamivudine
AtLaS Trial

Simplification to Atazanavir + Ritonavir + Lamivudine

AtLaS: Study Design

Study Design: AtLaS


- **Background:** Open-label, single-arm, simplification pilot study evaluating the safety and feasibility of treatment simplification to once-daily ritonavir-boosted atazanavir plus lamivudine in virologically suppressed patients with HIV infection
- **Inclusion Criteria (n=40)**
 - Age ≥ 18
 - On atazanavir/r + 2NRTIs for ≥ 6 months
 - Two HIV RNA < 50 copies/mL ≥ 3 months apart
 - CD4 count > 200 cells/mm³ for ≥ 6 months
- **Treatment Arms** (all once daily)
 - Atazanavir 300 mg + Ritonavir 100 mg + Lamivudine 300 mg once daily

**Atazanavir + Ritonavir +
Lamivudine once daily**
(n = 40)

Simplification to Atazanavir + Ritonavir + Lamivudine

AtLaS: Results


Week 48: Virologic Response (ITT, Discontinuation = Failure)



Simplification to Atazanavir + Ritonavir + Lamivudine

AtLaS: Results

Week 48: Change in Fasting Lipids from Baseline



Simplification to Atazanavir + Ritonavir + Lamivudine

AtLaS: Conclusions

Conclusion: “Simplification to atazanavir/ritonavir+lamivudine was apparently safe and associated with rare virological failure, without resistance selection. This strategy deserves further investigation in a randomized trial.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

